{
  "description": "A government attorney receives a concise memo analyzing recent Federal Circuit decisions on patent eligibility of biotech inventions, including extracted relevant passages, a plain\u2011English holding summary, properly formatted Bluebook citations, and permanent source URLs.",
  "messages": [
    {
      "role": "system",
      "content": "You are LexiResearch, an AI\u2011powered legal research assistant. Use the provided tools to locate, retrieve, extract, summarize, cite, and compile a research memo for the user\u2019s legal question."
    },
    {
      "role": "user",
      "content": "I need an analysis of recent Federal Circuit decisions on patent eligibility of biotech inventions, especially how the courts have applied the Supreme Court\u2019s Myriad decision. Please provide a concise summary, the key holdings, Bluebook citations, and links to the primary opinions."
    },
    {
      "role": "assistant",
      "content": "Let me locate the most recent Federal Circuit cases that discuss patent eligibility of biotech inventions in light of Myriad.",
      "tool_calls": [
        {
          "id": "search_law_database_a1b2c3",
          "name": "search_law_database",
          "arguments": {
            "query": "Federal Circuit patent eligibility biotech Myriad",
            "jurisdiction": "US Federal",
            "source": "case",
            "max_results": 5
          }
        }
      ]
    },
    {
      "role": "tool",
      "tool_call_id": "search_law_database_a1b2c3",
      "content": "## Search Results\n\n1. **In re Centocor Ortho Biotech, Inc., 2023 WL 1356789 (Fed. Cir. Jan. 12, 2023)**\n   *Excerpt:* The court applied *Myriad* and held that the claimed isolated antibody sequences were not patent\u2011eligible because they were not markedly different from naturally occurring antibodies.\n   *URL:* https://cite.case.law/fc/2023/1356789/\n\n2. **In re Alnylam Pharmaceuticals, Inc., 2022 WL 842019 (Fed. Cir. Oct. 5, 2022)**\n   *Excerpt:* The opinion discussed the scope of *Myriad* for RNA\u2011based inventions and concluded that the claimed siRNA constructs were patent\u2011eligible as they were not naturally occurring.\n   *URL:* https://cite.case.law/fc/2022/842019/\n\n3. **In re Becton, Dickinson & Co., 2021 WL 3120456 (Fed. Cir. June 15, 2021)**\n   *Excerpt:* The panel reiterated that isolated proteins must be markedly different from their natural counterparts to satisfy \u00a7101 after *Myriad*.\n   *URL:* https://cite.case.law/fc/2021/3120456/\n\n4. **In re Myriad Genetics, Inc., 2020 WL 1102847 (Fed. Cir. Mar. 3, 2020)**\n   *Excerpt:* The court reaffirmed the Supreme Court\u2019s holding that isolated DNA is not patent\u2011eligible, but emphasized that cDNA remains eligible.\n   *URL:* https://cite.case.law/fc/2020/1102847/\n\n5. **In re Amgen Inc., 2019 WL 2245639 (Fed. Cir. Dec. 20, 2019)**\n   *Excerpt:* The decision applied *Myriad* to a biotech method claim and found the claimed method patent\u2011eligible because it involved a non\u2011natural step.\n   *URL:* https://cite.case.law/fc/2019/2245639/"
    },
    {
      "role": "assistant",
      "content": "I will retrieve the full opinions for the two most relevant cases\u2014*In re Centocor Ortho Biotech* and *In re Alnylam Pharmaceuticals*\u2014and then extract the passages that discuss patent eligibility under *Myriad*.",
      "tool_calls": [
        {
          "id": "fetch_document_d4e5f6",
          "name": "fetch_document",
          "arguments": {
            "url": "https://cite.case.law/fc/2023/1356789/"
          }
        },
        {
          "id": "fetch_document_g7h8i9",
          "name": "fetch_document",
          "arguments": {
            "url": "https://cite.case.law/fc/2022/842019/"
          }
        }
      ]
    },
    {
      "role": "tool",
      "tool_call_id": "fetch_document_d4e5f6",
      "content": "```text\nIn re Centocor Ortho Biotech, Inc., 2023 WL 1356789 (Fed. Cir. Jan. 12, 2023)\n...\nThe court examined the claimed isolated antibody sequences. Relying on *Myriad* v.\u00a0Association for Molecular Pathology, the panel held that simply isolating a naturally occurring antibody does not satisfy 35\u202fU.S.C. \u00a7101 because the isolate is not markedly different from the naturally occurring molecule. The opinion emphasized that a patent\u2011eligible claim must recite a functional limitation or a structural modification that is not present in nature.\n...\nConclusion: The claims are invalid under \u00a7101.\n```"
    },
    {
      "role": "tool",
      "tool_call_id": "fetch_document_g7h8i9",
      "content": "```text\nIn re Alnylam Pharmaceuticals, Inc., 2022 WL 842019 (Fed. Cir. Oct. 5, 2022)\n...\nThe respondents argued that the claimed siRNA constructs were merely isolated forms of naturally occurring RNA sequences and therefore ineligible under *Myriad*. The court distinguished the case by noting that the siRNA molecules contain chemically modified nucleotides that do not occur in nature, creating a marked difference. Consequently, the court held the claims patent\u2011eligible under \u00a7101, emphasizing that *Myriad* does not bar claims directed to non\u2011natural modifications.\n...\nConclusion: The claims are patent\u2011eligible.\n```"
    },
    {
      "role": "assistant",
      "content": "Now I will extract the sections of each opinion that directly address the patent\u2011eligibility analysis under *Myriad*.",
      "tool_calls": [
        {
          "id": "extract_relevant_sections_j1k2l3",
          "name": "extract_relevant_sections",
          "arguments": {
            "document_text": "In re Centocor Ortho Biotech, Inc., 2023 WL 1356789 (Fed. Cir. Jan. 12, 2023)\n...\nThe court examined the claimed isolated antibody sequences. Relying on *Myriad* v.\u00a0Association for Molecular Pathology, the panel held that simply isolating a naturally occurring antibody does not satisfy 35\u202fU.S.C. \u00a7101 because the isolate is not markedly different from the naturally occurring molecule. The opinion emphasized that a patent\u2011eligible claim must recite a functional limitation or a structural modification that is not present in nature.\n...\nConclusion: The claims are invalid under \u00a7101.\n",
            "issue_description": "patent eligibility of isolated antibodies under Myriad"
          }
        },
        {
          "id": "extract_relevant_sections_m4n5o6",
          "name": "extract_relevant_sections",
          "arguments": {
            "document_text": "In re Alnylam Pharmaceuticals, Inc., 2022 WL 842019 (Fed. Cir. Oct. 5, 2022)\n...\nThe respondents argued that the claimed siRNA constructs were merely isolated forms of naturally occurring RNA sequences and therefore ineligible under *Myriad*. The court distinguished the case by noting that the siRNA molecules contain chemically modified nucleotides that do not occur in nature, creating a marked difference. Consequently, the court held the claims patent\u2011eligible under \u00a7101, emphasizing that *Myriad* does not bar claims directed to non\u2011natural modifications.\n...\nConclusion: The claims are patent\u2011eligible.\n",
            "issue_description": "patent eligibility of modified siRNA under Myriad"
          }
        }
      ]
    },
    {
      "role": "tool",
      "tool_call_id": "extract_relevant_sections_j1k2l3",
      "content": "- The court examined the claimed isolated antibody sequences. Relying on *Myriad* v.\u00a0Association for Molecular Pathology, the panel held that simply isolating a naturally occurring antibody does not satisfy 35\u202fU.S.C. \u00a7101 because the isolate is not **markedly different** from the naturally occurring molecule.\n- The opinion emphasized that a patent\u2011eligible claim must recite a functional limitation or a structural modification that is not present in nature.\n- **Conclusion:** The claims are **invalid** under \u00a7101."
    },
    {
      "role": "tool",
      "tool_call_id": "extract_relevant_sections_m4n5o6",
      "content": "- The respondents argued that the claimed siRNA constructs were merely isolated forms of naturally occurring RNA sequences and therefore ineligible under *Myriad*.\n- The court distinguished the case by noting that the siRNA molecules contain **chemically modified nucleotides** that do not occur in nature, creating a **marked difference**.\n- Consequently, the court held the claims **patent\u2011eligible** under \u00a7101, emphasizing that *Myriad* does **not** bar claims directed to non\u2011natural modifications.\n- **Conclusion:** The claims are **patent\u2011eligible**."
    },
    {
      "role": "assistant",
      "content": "Based on the extracted passages, I will generate a concise holding summary.",
      "tool_calls": [
        {
          "id": "summarize_holding_p7q8r9",
          "name": "summarize_holding",
          "arguments": {
            "extracted_sections": "- The court examined the claimed isolated antibody sequences. Relying on *Myriad* v.\u00a0Association for Molecular Pathology, the panel held that simply isolating a naturally occurring antibody does not satisfy 35\u202fU.S.C. \u00a7101 because the isolate is not **markedly different** from the naturally occurring molecule.\n- The opinion emphasized that a patent\u2011eligible claim must recite a functional limitation or a structural modification that is not present in nature.\n- **Conclusion:** The claims are **invalid** under \u00a7101.\n\n- The respondents argued that the claimed siRNA constructs were merely isolated forms of naturally occurring RNA sequences and therefore ineligible under *Myriad*.\n- The court distinguished the case by noting that the siRNA molecules contain **chemically modified nucleotides** that do not occur in nature, creating a **marked difference**.\n- Consequently, the court held the claims **patent\u2011eligible** under \u00a7101, emphasizing that *Myriad* does **not** bar claims directed to non\u2011natural modifications.\n- **Conclusion:** The claims are **patent\u2011eligible**."
          }
        }
      ]
    },
    {
      "role": "tool",
      "tool_call_id": "summarize_holding_p7q8r9",
      "content": "The Federal Circuit continues to apply *Myriad* as a test for whether a biotech claim is merely a natural product or a non\u2011natural invention.\n\n**Key holdings:**\n- **In re Centocor Ortho Biotech** \u2013 Isolating a naturally occurring antibody without any functional or structural change does **not** satisfy \u00a7101; the claim is invalid.\n- **In re Alnylam Pharmaceuticals** \u2013 Claims directed to siRNA molecules that incorporate chemically modified nucleotides **are** markedly different from natural RNA and therefore **eligible** under \u00a7101.\n\n**Takeaway:** To survive a \u00a7101 challenge post\u2011*Myriad*, a biotech claim must either (1) involve a non\u2011natural modification (e.g., chemical alteration, engineered sequence) or (2) recite a functional limitation that is not inherent in the natural counterpart."
    },
    {
      "role": "assistant",
      "content": "Next, I will format the case citations in proper Bluebook style.",
      "tool_calls": [
        {
          "id": "cite_cases_s1t2u3",
          "name": "cite_cases",
          "arguments": {
            "citations": [
              "In re Centocor Ortho Biotech, Inc., 2023 WL 1356789 (Fed. Cir. Jan. 12, 2023)",
              "In re Alnylam Pharmaceuticals, Inc., 2022 WL 842019 (Fed. Cir. Oct. 5, 2022)"
            ]
          }
        }
      ]
    },
    {
      "role": "tool",
      "tool_call_id": "cite_cases_s1t2u3",
      "content": "### Bibliography\n\n- *In re Centocor Ortho Biotech, Inc.*,\n  2023 WL 1356789 (Fed. Cir. Jan. 12, 2023).\n- *In re Alnylam Pharmaceuticals, Inc.*,\n  2022 WL 842019 (Fed. Cir. Oct. 5, 2022)."
    },
    {
      "role": "assistant",
      "content": "Now I will assemble the full research memo, including the summary, bibliography, and permanent URLs to the opinions.",
      "tool_calls": [
        {
          "id": "generate_report_v4w5x6",
          "name": "generate_report",
          "arguments": {
            "summary": "The Federal Circuit continues to apply *Myriad* as a test for whether a biotech claim is merely a natural product or a non\u2011natural invention.\n\n**Key holdings:**\n- **In re Centocor Ortho Biotech** \u2013 Isolating a naturally occurring antibody without any functional or structural change does **not** satisfy \u00a7101; the claim is invalid.\n- **In re Alnylam Pharmaceuticals** \u2013 Claims directed to siRNA molecules that incorporate chemically modified nucleotides **are** markedly different from natural RNA and therefore **eligible** under \u00a7101.\n\n**Takeaway:** To survive a \u00a7101 challenge post\u2011*Myriad*, a biotech claim must either (1) involve a non\u2011natural modification (e.g., chemical alteration, engineered sequence) or (2) recite a functional limitation that is not inherent in the natural counterpart.",
            "bibliography": "### Bibliography\n\n- *In re Centocor Ortho Biotech, Inc.*,\n  2023 WL 1356789 (Fed. Cir. Jan. 12, 2023).\n- *In re Alnylam Pharmaceuticals, Inc.*,\n  2022 WL 842019 (Fed. Cir. Oct. 5, 2022).",
            "source_links": [
              "https://cite.case.law/fc/2023/1356789/",
              "https://cite.case.law/fc/2022/842019/"
            ]
          }
        }
      ]
    },
    {
      "role": "tool",
      "tool_call_id": "generate_report_v4w5x6",
      "content": "## Memorandum: Federal Circuit Patent\u2011Eligibility Analysis for Biotech Inventions (Post\u2011*Myriad*)\n\n**To:** Government Attorney\n**From:** LexiResearch \u2013 AI Legal Research Assistant\n**Date:** December 8, 2025\n**Re:** Recent Federal Circuit decisions on patent eligibility of biotech inventions under *Myriad*.\n\n---\n\n### Summary\nThe Federal Circuit continues to apply *Myriad* as a test for whether a biotech claim is merely a natural product or a non\u2011natural invention.\n\n**Key holdings:**\n- **In re Centocor Ortho Biotech** \u2013 Isolating a naturally occurring antibody without any functional or structural change does **not** satisfy \u00a7101; the claim is invalid.\n- **In re Alnylam Pharmaceuticals** \u2013 Claims directed to siRNA molecules that incorporate chemically modified nucleotides **are** markedly different from natural RNA and therefore **eligible** under \u00a7101.\n\n**Takeaway:** To survive a \u00a7101 challenge post\u2011*Myriad*, a biotech claim must either (1) involve a non\u2011natural modification (e.g., chemical alteration, engineered sequence) or (2) recite a functional limitation that is not inherent in the natural counterpart.\n\n---\n\n### Bibliography\n\n- *In re Centocor Ortho Biotech, Inc.*,\n  2023 WL 1356789 (Fed. Cir. Jan. 12, 2023).\n- *In re Alnylam Pharmaceuticals, Inc.*,\n  2022 WL 842019 (Fed. Cir. Oct. 5, 2022).\n\n---\n\n### Source Links\n\n- [Centocor Ortho Biotech Opinion (Fed. Cir. 2023)](https://cite.case.law/fc/2023/1356789/)\n- [Alnylam Pharmaceuticals Opinion (Fed. Cir. 2022)](https://cite.case.law/fc/2022/842019/)\n\n---\n\n*Prepared by LexiResearch. This memo is for attorney review and should be verified against the primary sources before reliance.*"
    },
    {
      "role": "assistant",
      "content": "Here is the completed research memo. It includes a concise analysis of the two recent Federal Circuit cases, the key holdings on patent eligibility after *Myriad*, properly formatted Bluebook citations, and direct links to the full opinions. Let me know if you need further detail or additional cases.",
      "tool_calls": []
    }
  ]
}